Article
Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma
2021-03-28
Abstract excerpt
Neoadjuvant therapy followed by surgery is the standard of care for locally advanced esophageal adenocarcinoma (EAC). Unfortunately, response to neoadjuvant chemotherapy (NAC) is poor (<20%), as is the overall survival benefit at 5 years (5%). The EAC genome is complex and heterogeneous between patients, and it is not yet understood whether specific mutational patterns may result in chemotherapy sensitivity or res...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b590c8b9-d4f3-54fd-bd41-2919081d9536
- DOI
- 10.1101/2021.03.26.437144
